

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Neurology				
Stroke	Histone deacetylase 6 (HDAC6)	<p>Studies in mice suggest HDAC6 inhibitors could be useful for treating ischemic stroke. In a mouse model of ischemic stroke, a selective HDAC6 inhibitor increased expression of regulatory T cell markers and decreased infarct size compared with vehicle. Next steps could include testing HDAC6 inhibitors in other preclinical stroke models.</p> <p>Celgene Corp. and Acetylon Pharmaceuticals Inc. have the HDAC6 inhibitor ACY-1215 in Phase I/II testing to treat multiple myeloma (MM). Karus Therapeutics Ltd. has HDAC6 inhibitors in preclinical development to treat cancer and inflammation.</p> <p>SciBX 6(48); doi:10.1038/scibx.2013.1397 Published online Dec. 19, 2013</p>	Patent and licensing status undisclosed	<p>Liesz, A. <i>et al. J. Neurosci.</i>; published online Oct. 30, 2013; doi:10.1523/JNEUROSCI.4901-12.2013</p> <p>Contact: Roland Veltkamp, Heidelberg University, Heidelberg, Germany e-mail: roland.veltkamp@med.uni-heidelberg.de</p>